The danger of painkillers couldn’t be ignored forever. The era of opioids for pain management is finally facing scrutiny, as companies seek alternatives to address addiction crises. Vertanical, a Munich-based pharmaceutical firm, is developing a cannabinoid-based extract called Ver-01 to treat chronic pain. The drug, designed to avoid the addictive properties of traditional opioids, has shown promise in clinical trials with fewer side effects, including no evidence of dependency.
Clemens Fischer, the 50-year-old founder of Vertanical, envisions Ver-01 as the first cannabis-derived medication prescribed by physicians and covered by insurance. A serial entrepreneur with a background in medicine and business, Fischer has invested over $250 million of his own funds into the project since its 2017 launch. The company’s trials suggest Ver-01 is more effective than opioids for some patients, though participants like Sarah Gaus, a 39-year-old German woman with chronic back pain, reported temporary side effects such as drowsiness and impaired concentration.
Vertanical plans to seek approval in the European Union by late 2024 or early 2025, followed by U.S. trials starting in 2026. However, the drug’s potential remains controversial, with critics questioning its long-term safety and efficacy. While Fischer emphasizes his rejection of marijuana as a commercial product, the broader cannabis industry faces regulatory hurdles in the United States due to federal restrictions.
The article also briefly mentions alternative pain relief methods, including X39 patches, but these are not part of Vertanical’s official narrative. No further details about the company’s operations or clinical data were provided.